Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
From Oct. 11 through Nov. 6, shares of Eli Lilly fell 16.7%, largely in response to third-quarter results that missed Wall Street expectations. Management also lowered the midpoint of its 2024 earning ...
GIPR is involved in insulin release and glycemic control. Rival drugs from Eli Lilly and Viking Therapeutics also target GIPR, but they mimic it. Renza noted the placebo group had a higher bone ...